TRT's 'honeymoon crash': what actually causes it and how long it lasts

What did @alphaclubsupps actually say?

The creator describes a pattern many men on TRT report but rarely see explained: an initial "supercharged" feeling in week one, followed by a crash when the body's own testosterone production shuts down. His framing is that the early high comes from stacking exogenous testosterone on top of still-active endogenous production, and the subsequent dip happens as the hypothalamic-pituitary-gonadal (HPG) axis suppresses. He calls this "completely normal" and says getting TRT dialed in takes "a good few months." He also pitches his own packages at the end, which is worth flagging.

The core physiological story he's telling is recognizable and broadly consistent with how testosterone suppression works. The framing of "doubled up" testosterone in week one is a bit loose, but the underlying concept isn't wrong. Credit where it's due: this is a conversation most TRT content skips entirely.

Does the science back this up?

Mostly, yes, though the timeline and mechanism deserve more precision than he offers. The HPG axis suppression isn't a clean two-week switch. It's a gradual process, and the degree and speed varies by individual, prior testosterone levels, and the ester used.

Endogenous testosterone suppression following exogenous administration is well-documented. Testosterone esters like cypionate or enanthate suppress LH and FSH within days of administration, not weeks. Coviello et al. (2004, Journal of Clinical Endocrinology and Metabolism) showed that LH suppression begins almost immediately after injection, though full suppression of testicular production takes longer. The "dip" he describes is plausible, but it's not simply a matter of waiting two weeks for your natural system to shut off. Suppression is already underway in week one. The emotional and mood symptoms he describes, including irritability and low mood during dose adjustment, are consistent with fluctuating serum testosterone levels, particularly with longer-acting injectable esters that produce peak-and-trough cycles. Zitzmann et al. (2006, Journal of Clinical Endocrinology and Metabolism) documented mood variability linked to testosterone fluctuations in hypogonadal men.

What did they get wrong (or right)?

The "doubled up" framing is the weakest part of this video. It implies your total testosterone in week one is roughly double your baseline plus your injected dose. That's not quite how it works. Suppression of endogenous production begins almost immediately, so the overlap window is shorter and less additive than he suggests. You might get a brief spike, but calling it "doubled up" for a full week overstates it.

What he gets right is the emotional arc. The pattern of early enthusiasm followed by a rough middle period is real, and the psychological impact of that dip is underappreciated. Men who feel great in week one and terrible in week three often do assume something is broken. Telling them this is expected is genuinely useful.

The "marathon not a sprint" framing around months of stabilization is also supported by clinical observation. Wang et al. (2000, Journal of Clinical Endocrinology and Metabolism) found that mood, energy, and sexual function improvements from TRT continued to develop over three to six months. The instinct to judge TRT efficacy in the first few weeks is premature.

What should you actually know?

If you're starting TRT and feel great in week one, don't treat that as your baseline. And if you crash in week two or three, don't panic and don't assume the protocol is wrong before it's had time to stabilize. That said, "completely normal" should not be a reason to dismiss symptoms entirely. Severe mood changes, significant anxiety, or prolonged low energy past the first month warrant a conversation with your prescribing clinician, not a supplement package from a TikTok creator.

The timeline for genuine stabilization depends heavily on which formulation you're using. Injectables produce larger fluctuations than gels or patches, and injection frequency matters. Weekly or twice-weekly injections produce more stable serum levels than biweekly dosing, which is why many clinicians have moved away from every-two-weeks protocols. Rastrelli et al. (2019, Sexual Medicine Reviews) summarized that testosterone formulation choice significantly impacts symptom consistency and patient experience during early treatment.

• HPG axis suppression begins within days, not weeks, of starting exogenous testosterone.
• Early mood symptoms and energy fluctuations are real and expected, but not indefinite.
• Three to six months is a reasonable window to evaluate TRT effectiveness, not three weeks.
• Injection frequency affects how pronounced the peak-and-trough experience is.
• This creator is selling packages. His clinical framing may be shaped by that interest.